Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 382

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Practice Guidelines for the Management of Patients with Histoplasmosis

Open access
Wheat, J., Sarosi, G., McKinsey, D., Hamill, R., Bradsher, R., Johnson, P., Loyd, J., Kauffman, C.·2000·Clinical Infectious Diseases

Abstract

Objective. The objective of this guideline is to provide recommendations for treating patients with the more common forms of histoplasmosis. Participants and consensus process. A working group of 8 experts in this field was convened to develop this guideline. The working group developed and refined the guideline through a series of conference calls. Outcomes. The goal of treatment is to eradicate the infection when possible, although chronic suppression may be adequate for patients with AIDS and other serious immunosuppressive disorders. Other important outcomes are resolution of clinical abnormalities and prevention of relapse. Evidence. The published literature on the management of histoplasmosis was reviewed. Controlled trials have been conducted that address the treatment of chronic pulmonary and disseminated histoplasmosis, but clinical experience and descriptive studies provide the basis for recommendations for other forms of histoplasmosis. Value. Value was assigned on the basis of the strength of the evidence supporting treatment recommendations, with the highest value assigned to controlled trials, according to conventions established for developing practice guidelines. Benefits and costs. Certain forms of histoplasmosis cause life-threatening illnesses and result in considerable morbidity, whereas other manifestations cause no symptoms or minor self-limited illnesses. The nonprogressive forms of histoplasmosis, however, may reduce functional capacity, affecting work capacity and quality of life for several months. Treatment is clearly beneficial and cost-effective for patients with progressive forms of histoplasmosis, such as chronic pulmonary or disseminated infection. It remains unknown whether treatment improves the outcome for patients with the self-limited manifestations, since this patient population has not been studied. Other chronic progressive forms of histoplasmosis are not responsive to pharmacologic treatment. Treatment options. Options for therapy for histoplasmosis include ketoconazole, itraconazole, fluconazole, amphotericin B (Fungizone; Bristol-Meyer Squibb, Princeton, NJ), liposomal amphotericin B (AmBisome; Fujisawa, Deerfield, IL), amphotericin B colloidal suspension (ABCD, or Amphotec; Seques, Menlo Park, CA), and amphotericin B lipid complex (ABLC, or Abelcet; Liposome, Princeton, NJ). Histoplasma capsulatum is endemic in certain areas of North and Latin America, but cases have also been reported from Europe and Asia. In the United States, most cases have occurred within the Ohio and Mississippi River valleys. Precise reasons for this endemic distribution pattern are unknown but are thought to include moderate climate, humidity, and soil characteristics. Bird and bat excrement enhances the growth of the organism in soil by accelerating sporulation. These unique growth requirements explain, in part, the localization of histoplasmosis into so-called microfoci. Activities that disturb such sites are associated with exposure to H. capsulatum. Air currents carry the spores for miles, exposing individuals who were unaware of contact with the contaminated site. Furthermore, environmental sites that are not visibly contaminated with droppings may harbor the organism, making it difficult to suspect histoplasmosis in most cases. Severity of illness after inhalation exposure to H. capsulatum varies, depending on the intensity of exposure and the immunity of the host. Asymptomatic infection or mild pulmonary disease follows low-intensity exposures in healthy individuals, whereas heavy exposure may cause severe diffuse pulmonary infection. Hematogenous dissemination from the lungs to other tissues probably occurs in all infected individuals during the first 2 weeks of infection before specific immunity has developed, but is nonprogressive in the majority of cases, which leads to the development of calcified granulomas in the liver and/or spleen. Progressive dissemination occurs primarily in those with underlying immunosuppressive disorders or those at the extremes of age. Progressive pulmonary infection is common in patients with underlying centrilobular emphysema. A variety of acute and chronic manifestations of histoplasmosis appear to result from unusual inflammatory or fibrotic responses to the infection, including rheumatologic syndromes and pericarditis during the first year after exposure, and chronic mediastinal inflammation or fibrosis, broncholithiasis, and enlarging parenchymal granulomas occurring later. A variety of treatment options are available, but first the decision must be made to treat or to observe, since most patients with histoplasmosis recover without therapy (table 1). Specific treatment recommendations for the more common types of histoplasmosis are reviewed below and in table 2. Fever, chills, headache, myalgia, anorexia, cough, and chest pain characterize this form of histoplasmosis and are seen in 85%–100% of cases. Patients may experience pleuritic pain. The

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/313752

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 382

Metadata

Authors
Wheat, J., Sarosi, G., McKinsey, D., Hamill, R., Bradsher, R., Johnson, P., Loyd, J., & Kauffman, C.
Venue
Clinical Infectious Diseases
Published
2000-04-01
Volume
30
Issue
4
Pages
688-695
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2122475397
Cited by
382
References
33
FWCI
18.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.